Last Updated on February 18, 2021 by The Health Master
Dr Reddy’s Laboratories Ltd announced the launch of Capecitabine tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA).
The Xeloda brand and generic had US sales of approximately $90 million MAT for the most recent twelve months ending in October 2020, according to IQVIA Health.
Dr Reddy’s capecitabine tablets, USP are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.
Also read:
Glenmark launches Kidney drug at 96% lower price
Lupin, Aurobindo units recall medicines in US market
Alembic gets USFDA final nod for Treprostinil injection
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Go to main website, click here
Follow and connect with us on Facebook and Linkedin
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
